Products listed by Liaoning Chengda Biological Co., Ltd.

Through "introduction, digestion, absorption and re-innovation", the company has mastered the "technology platform for large-scale preparation of vaccines by bioreactor", which has overcome the technical problem of preparing high-quality vaccines by large-scale animal cell culture in China for more than ten years. The "Chengda Suda" human rabies vaccine produced by this technology has broken the long-term monopoly of high-end human rabies vaccine in China by multinational companies, and all technical indicators have reached the advanced level of similar products in the world. It has become the first brand of rabies vaccine for people in China, exported to more than ten countries such as India, and its products are being registered in many countries such as Viet Nam.

After the listing of Chengda Suda, a large number of phase 4 clinical observations have been carried out at home and abroad, and rich clinical research data have been accumulated. At present, Chengda Suda human rabies vaccine has been inoculated to nearly 20 million people, and no case of complete immunization failure has been found so far. It is the first choice vaccine for rabies prevention and control in China. The swine fever vaccine produced by high-density culture of miniature pig kidney cells (MPK cells) in advanced bioreactors introduced from abroad is currently in the stage of technical docking. This product is produced and used in Italy and other countries, and it is a low-cost and high-quality product.

With the subsequent products coming on the market one after another, with the leading technical indicators and product quality, it is expected to become a new profit growth point for the company.